

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, September 16, 2021

1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/95637452651 Webinar ID: 956 3745 2651 Password: 761794	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 956 3745 2651 Passcode: 761794

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Qelbree™ (Stimulants and Related Agents)
 - ii. Zegalogue® (Endocrine and Metabolic agents: glucagon agents)
 - iii. Koselugo™ (Non-PDL drug class agent requiring PA - Oral Oncology)
 - iv. Ponvory™ (Multiple Sclerosis agents)
 - v. Lumakras™ (Non-PDL drug class agent requiring PA – Oral Oncology)
 - vi. Fotivda™ (Non-PDL drug class agent requiring PA – Oral Oncology)
 - vii. Truseltiq™ (Non-PDL drug class agent requiring PA – Oral Oncology)
 - viii. Gemtesa™ (Bladder relaxants)
- I. Therapeutic Classes with Recommended Changes**
 - a. Antidepressants, Other
 - b. Antidepressants, SSRIs
 - c. Movement Disorders
 - d. Stimulants and Related Agents
- V. Consent Agenda**
 - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Alzheimer’s Agents	Beta Blockers
Angiotensin Receptor Blockers	Bladder Relaxant Preparations
Angiotensin Modulator Combinations	BPH Treatments
Antianginal & Anti-Ischemic	Calcium Channel Blockers

Antiarrhythmics, Oral	Lipotropics, Other
Anticoagulants	Lipotropics, Statins
Anticonvulsants	Opiate Dependence Treatments
Antidepressants - Tricyclics	PAH Agents- Oral and Inhaled
Antiparkinson's Agents	Platelet Aggregation Inhibitors
Antipsychotics	Sedative Hypnotics
Anxiolytics	Tobacco Cessation Products

V. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **November 18, 2021**
 - ii. **January 20, 2022**
 - iii. **March 17, 2022**
 - iv. **May 19, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: <https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.